SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (18531)4/2/1998 4:05:00 PM
From: WTDEC  Respond to of 32384
 
" approval is based on a risk-reward formula"

Henry, a risk-reward approach to drug approval makes sense to me. I guess my paranoia is showing again. I assume side effects need to be considered when contemplating off-label use for less serious diseases.

Thanks,

Walter



To: Henry Niman who wrote (18531)4/2/1998 9:56:00 PM
From: John O'Neill  Read Replies (1) | Respond to of 32384
 
Henry N. speaking of deals...why would LGND even consider taking Seragen's drug (without Psoriasis element). It appears, on the surface that this would show very poor judgement of part of LGND's mgmt.

JO


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News